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Abstract
The striking and complex phenotype of Cockayne syndrome (CS) patients combines progeria-like features with devel-
opmental deficits. Since the establishment of the in vitro culture of skin fibroblasts derived from patients with CS in the
1970s, significant progress has been made in the understanding of the genetic alterations associated with the disease
and their impact on molecular, cellular, and organismal functions. In this review, we provide a historic perspective on the
research into CS by revisiting seminal papers in this field. We highlighted the great contributions of several researchers
in the last decades, ranging from the cloning and characterization of CS genes to the molecular dissection of their roles
in DNA repair, transcription, redox processes and metabolism control. We also provide a detailed description of all
pathological mutations in genes ERCC6 and ERCC8 reported to date and their impact on CS-related proteins. Finally,
we review the contributions (and limitations) of many genetic animal models to the study of CS and how cutting-edge
technologies, such as cell reprogramming and state-of-the-art genome editing, are helping us to address unanswered
questions.
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The epidemiology of Cockayne Syndrome (CS)
and the discovery of the CS genes
Edward Alfred Cockayne first described CS in 1936.
He diagnosed it in two young siblings (born to healthy par-
ents) that displayed a set of very similar characteristics that
included skin photosensitivity, short stature, prominent supe-
rior maxillae, disproportionally large hands and feet, sunken
eyes with retinal atrophy, hearing impairment, below-ave-
rage intelligence, a severely limited speaking ability, and
muscle contraction, conditions that would later become char-
acteristic of CS patients (Cockayne, 1936, 1946; Laugel,
2013). Subsequent reports also confirmed that patients with
CS feature complex and heterogeneous neuropathology that
includes calcification of the basal ganglia, cerebellar atrophy,
loss of Purkinje and granular cells, hyperchromatic macro-
glial cells, microcephaly, and patchy demyelination (Guar-
diola et al., 1999; Karam et al., 2000; Weidenheim et al.,
2009; Wilson et al., 2015; Karikkineth et al., 2017).
CS is an autosomal recessive disorder with a preva-
lence of ~2.7 per million births in Western Europe and in Ja-
pan (Kleijer et al., 2008; Kubota et al., 2015). The phenotype
of the patients can range from mild to very severe and is sub-
divided into three types. The classical type (type I) corre-
sponds to the moderate phenotype in which life expectancy is
16 years. In type II (the most severe and with the earliest on-
set), life expectancy is 5 years, whereas in the third type (mild
and atypical), the phenotype manifests itself later in life, with
life expectancy above 30 years. In all cases, pneumonia/re-
spiratory ailments are the most common causes of death
(Natale, 2010).
In vitro culture of skin fibroblasts derived from patients
with CS in the 1970s was the first step toward the develop-
ment of experimental models of the disease. CS fibroblasts
are characterized by extreme sensitivity to ultraviolet light
(UV) despite a normal ability to excise pyrimidine-dimers
from the genome (Schmickel et al., 1977; Andrews et al.,
1978). In fact, CS cells display a marked defect in the recov-
ery of RNA synthesis after UV irradiation (Mayne and Leh-
mann, 1982) owing to a failure in the repair of transcrip-
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tionally active genes (Venema et al., 1990; van Hoffen et al.,
1993). By evaluation of post-UV RNA synthesis recovery in
multinucleated cells obtained by the fusion of cells from dif-
ferent CS donors, three complementation groups (A, B, and
C) were initially identified (Tanaka et al., 1981; Lehmann,
1982). Group C identified by Lehmann corresponded to a pa-
tient that had combined features of CS and xeroderma pig-
mentosum (XP). Patients that fall in this category (termed
XP/CS) manifest, in addition to CS features, the classical XP
characteristics (skin pigmentation and extremely high skin
cancer predisposition) and harbor mutations in the genes
XPB, XPD, XPG, or (more recently identified) XPF or
ERCC1 (Weeda et al., 1990; Kashiyama et al., 2013;
Lehmann et al., 2014; Moriel-Carretero et al., 2015).
In the 1990s, the genes corresponding to groups A and
B were cloned, characterized, and termed CSA and CSB, re-
spectively. CSB was originally termed ERCC6 (excision re-
pair cross-complementation group 6) because it was found to
complement the nucleotide excision repair (NER) defect of
the Chinese Hamster Ovary mutant cell line UV61, a repre-
sentative of complementation group 6 of rodent cell lines de-
fective in excision repair (Troelstra et al., 1990). Two years
later, Hoeijmaker’s group demonstrated that the expression
of this gene could reverse UV sensitivity and rescue post-UV
RNA synthesis in a cell line (CS1AN) assigned to CS group
B but not in group A cells (Troelstra et al., 1992). Another
two years later, using episomal vectors to drive the expres-
sion of a cDNA library, Friedberg’s group was able to iden-
tify the gene capable of reversing the UV sensitivity of CS
cells from group A (but not B) and to reactivate the expres-
sion of a UV-inactivated reporter gene (Henning et al., 1995).
They discovered that the CSA protein, encoded by ERCC8
(Itoh et al., 1996), can interact with the CSB protein. Both
genes play a critical role in the transcription-coupled nucleo-
tide excision repair (TC-NER) of damaged DNA, which is
described below in more detail.
CSA and CSB in TC-NER
Cells evolved complex and refined mechanisms to pre-
vent genome instability in response to the presence of exoge-
nously and endogenously generated DNA lesions. One of
these mechanisms, conserved from bacteria to humans, is the
NER pathway (Schärer, 2013; Marteijn et al., 2014; Gre-
gersen and Svejstrup, 2018). This system drives the repair of
bulky distorting DNA lesions (such as those induced by UV
and by some redox processes) in four sequential steps: i) de-
tection of a lesion, ii) excision of a DNA single-strand frag-
ment containing the lesion, iii) DNA synthesis by a polymer-
ase to fill the gap, and iv) nick sealing by a ligase (Costa et al.,
2003; Reardon and Sancar, 2005; Menck and Munford,
2014). In bacteria, three proteins (UvrA, UvrB, and UvrC)
are critical for the detection and excision of the lesion
(Seeberg and Strike, 1976; Sancar and Rupp, 1983), whereas
in humans, more than 30 proteins acting in an orchestrated
manner are required for these steps, as reviewed elsewhere in
detail (Menck and Munford, 2014). NER is subdivided into
two sub-pathways: global genome repair (GG-NER) and
transcription-coupled repair (TC-NER). They differ in how
DNA lesions are detected, although the excision and DNA
re-synthesis steps are shared by the two pathways (Menck
and Munford, 2014). In humans, GG-NER is initiated by the
XPC protein (Sugasawa et al., 1998), which is constantly
scanning the whole genome for the presence of helix-dis-
torting lesions (Hoogstraten et al., 2008), and the detection of
UV products is facilitated by XPE/DDB2 (Cleaver et al.,
2009). In TC-NER, as shown in Figure 1, the triggering event
is the arrest of RNA polymerase II (RNA pol II) owing to the
presence of a lesion in the actively transcribed strand of a
gene (Bohr et al., 1985; Hanawalt and Spivak, 2008). It is in
this pathway that the CSA and CSB proteins play a critical
part. Upon RNA pol II blockade, the binding of CSB to RNA
pol II is stabilized (Tantin et al., 1997; van den Boom et al.,
2004; Fousteri et al., 2006) and CSB then wraps DNA around
itself, altering its conformation and recruiting histone acetyl-
transferase p300 and core NER factors (such as RPA, XPG,
and TFIIH) to RNA pol II arrest sites (Fousteri et al., 2006),
as presented in Figure 1 (upper panel). CSB also recruits an
E3-ubiquitin ligase complex, highlighted in green, composed
of CSA (which contains WD motifs involved in protein–pro-
tein interactions), DDB1, Cullin 4A, and ROC1/Rbx1 pro-
teins (Groisman et al., 2003; Fousteri et al., 2006). Although
CSA is not necessary for the recruitment of NER factors, it is
required for recruiting HMGN1, XAB2, and TFIIS to RNA
pol II arrest sites (Fousteri et al., 2006). XAB2 is an XPA-
interacting protein (Nakatsu et al., 2000) and might act as a
scaffolding factor for protein assembly during TC-NER
(Fousteri and Mullenders, 2008), while the nucleosome-bin-
ding protein, HMGN1, was suggested to promote chromatin
changes that allow for the incision step (Fousteri and
Mullenders, 2008).
The fates of the nascent transcript and that of the stalled
RNA pol II are still debated. One hypothesis is that transcript
cleavage may occur in an elongation factor for RNA pol II
(ELL)-dependent manner (Gregersen and Svejstrup, 2018).
As for the stalled RNA pol II — which occupies a space that
ranges from 25 nucleotides downstream of the lesion to 10
nucleotides upstream (Spivak and Ganesan, 2014), thus im-
pairing the assembly of NER factors — it may undergo re-
verse translocation/backtracking (Donahue et al., 1994;
Fousteri et al., 2006) or be targeted for proteasomal degrada-
tion by ubiquitination (Harreman et al., 2009), as shown in
Figure 1 (lower panel).
Upon lesion resolution, the CSA-E3 ubiquitin ligase
complex performs a critical function in the recovery of tran-
scription by targeting CSB for proteasomal degradation
(Groisman et al., 2006). To avoid premature degradation of
CSB, UVSSA, which binds firmly to stalled RNA pol II, re-
cruits USP7, an enzyme that promotes deubiquitination of
CSB (Schwertman et al., 2012), highlighted in blue in Figure
1. Therefore, once the DNA lesion is removed, USP7-
mediated deubiquitination of CSB ceases, and CSB is finally
targeted for degradation.
In the absence of the CSA or CSB protein, the arrest of
RNA pol II persists, an event that leads to p53 activation and
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cell death, thus explaining the extreme sensitivity of CS cells
to UV damage (Ljungman and Zhang, 1996). Besides its par-
ticipation in TC-NER, proteins CSA and CSB play several
other important roles. In the following sections, we provide
detailed descriptions of the structures of these proteins, their
functions outside of TC-NER, and a comprehensive review
of pathological mutations, their consequences for protein
function, and their association with patients’ clinical charac-
teristics.
The structure and functions of proteins CSA
and CSB, or how pathological mutations are
(not) associated with clinical phenotypes
CSB is a 168 kDa protein composed of 1493 amino
acid residues and is encoded by the ERCC6 gene located in
chromosomal region 10q11 (Troelstra et al., 1992, 1993). It
belongs to the SWI2/SNF2 family of helicases, and just as all
the proteins in this family, it does not have the capacity to
open the DNA double helix (Selby and Sancar, 1997a). In
contrast, the SWI2/SNF2 proteins temporarily modify DNA
conformation via ATP hydrolysis, thereby altering the DNA
contact with histones and nucleosome positioning. There-
fore, SWI2/SNF2 proteins are considered chromatin remo-
delers (Lusser and Kadonaga, 2003; Beerens et al., 2005). In
addition to its known classic function in TC-NER, CSB takes
part in the regulation of transcription and assists with nuclear
and mitochondrial base excision repair (BER). It has been re-
ported that CSB interacts with proteins XPB, XPD, XPG,
TFIIH, RNA pol I and II, and glycosylases (Tantin, 1998;
Bradsher et al., 2002; Tuo et al., 2002; Sarker et al., 2005;
Stevnsner et al., 2008; Kamenisch et al., 2010), although
some of these interactions were described only once and need
additional confirmation of their biological relevance.
The CSB structure mainly includes the following do-
mains: an acidic domain, SNF2/ATPase region, ubiquitin-
binding domain, and a nuclear localization signal (Liu et al.,
2015). The acidic domain comprising amino acid residues
356 to 394 is located in the N-terminal portion, which is
mostly negatively charged (Troelstra et al., 1992). In other
proteins, this domain facilitates protein–protein interactions,
especially those of nuclear and DNA-binding proteins, such
as transcriptional activators and chromatin remodelers (Mel-
cher, 2000; Carpenter et al., 2005; Wu et al., 2017). Given
that CSB is classified as a chromatin remodeler, it has been
hypothesized that its acidic domain facilitate this activity, but
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Figure 1 - Physical blockage of RNA polymerase II facilitates CSB binding to it. The following is responsible for recruiting p300, CSA and the other
NER factors. CSA, together with CUL4, RBX1 and DDB1 are constantly ubiquitinating CSB, however UVSSA-USP7 complex are constantly removing
ubiquitin tags from it. CSA also recruits HMGN1, which together with p300 unwinds chromatin upstream RNApol II, allowing it to backtrack and expose
the lesion site to NER factors. TFIIS stimulates RNA cleavage by RNApol II during this process. NER factors unwinds DNA around the lesion. While
RPA protects ssDNA from degradation, XPG and XPF-ERCC1 endonucleases cleave the strand containing the lesion. DNA polymerase and ligase then
fill up the gap. CSB degradation is necessary to RNA synthesis recovery.
the possible underlying mechanisms have not yet been fully
elucidated (Brosh et al., 1999).
Mutations in the acidic domain of CSB in UV61 cells
do not compromise the ability to repair lesions caused by UV,
4-QNO (4-Nitroquinoline 1-oxide), and NA-AAF (N-ace-
toxy-2-acetylaminofluorene), or cell viability after exposure
to these agents (Brosh et al., 1999; Sunesen et al., 2000).
These data indicate that the integrity of this domain is not es-
sential for this protein’s function in TC-NER. Similar results
were obtained by Lake et al. (2010) with UV irradiation of
CS1AN-SV cells expressing CSB protein lacking the first
454 amino acid residues in the N-terminal portion, demon-
strating that the absence of this region does not compromise
the ability of the protein to associate with chromatin but in-
stead makes such associations much more frequent even
without UV exposure. It was also observed that this deletion
increases the ATPase activity of CSB, indicating that the
N-terminal portion acts as a negative regulator of its associa-
tion with chromatin via ATP hydrolysis (Lake et al., 2010).
CSB protein structure and homozygous and heterozygous
pathological alterations are illustrated in Figure 2 A and B,
whereas Table S1 lists all ERCC6 mutations reported in the
literature.
The nuclear localization signal is found within regions
466–481 and 1038–1055 (amino acid positions) (Lange et
al., 2007). In a recent work, Iyama et al. (2018) identified
through computational analysis the existence of a third re-
gion of nuclear localization signal, in addition to the three nu-
cleolar localization signals that cooperate for the distribution
of the protein between the nucleus and nucleolus.
Among these regions there is also the SNF2/ATPase
domain, which is highly conserved in the SWI2/SNF2 family
(Pazin and Kadonaga, 1997). This domain extends from
amino acid residue 510 to residue 960 and contains seven
ATPase motifs: I, Ia, II, II, IV, V, and VI (Troelstra et al.,
1992), essential for the functioning of the protein (Brosh et
al., 1999; Selzer et al., 2002). The function of the ATPase re-
gion is the most relevant for the activity of CSB, because this
function provides energy for its association with (and remod-
eling of) chromatin by altering the positioning of nucleo-
somes (Citterio et al., 2000). Through this activity, CSB
enables the repair of DNA lesions by promoting the access of
other proteins, such as CSA and NER factors, to the site of
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Figure 2 - Representation of CSB protein and domains. Acidic region (A), nuclear localization signal (N), helicase motifs (I, Ia –VI) and ubiquitin bind-
ing domain (UBD). (A) Homozygous mutations are indicated: frameshifts and nonsense mutations are indicated above the protein, while deletions and
missense mutations are indicated below the protein. (B) Represents heterozygous mutations.
stalled RNA pol II (Stadler and Richly, 2017). During the
transcription process, CSB alters in situ chromatin conforma-
tion, favoring the binding of transcription factors (Lake et al.,
2014).
To understand and characterize the functional impor-
tance of each ATPase motif, several cell lines carrying muta-
tions in different and highly conserved regions in these mo-
tifs have been created. In general, amino acid substitutions in
these regions decrease cell survival, RNA synthesis recovery,
and DNA repair after exposure to UV, as well as increase the
sensitivity to 4-NQO (Brosh et al., 1999; Muftuoglu et al.,
2002; Selzer et al., 2002). Notably, mutations in domains I
and II, named “Walker A” and “Walker B,” respectively, can
completely inactivate the ATPase activity (Citterio et al.,
1998; Christiansen et al., 2003). Mutations in motifs V and
VI also compromise the ATPase activity, although to a lesser
extent (Christiansen et al., 2003). Different motifs can also
contribute in different ways to other activities carried out by
CSB. Tuo et al. (2001) demonstrated that cells mutated in
motifs V and VI are more sensitive to -radiation than wild-
type cells, and DNA lesions such as 7,8-dyhydro-2’-deo-
xyguanosine (8-oxoGua) accumulate in CSB-null and VI
mutant-CSB cells after exposure to -radiation, indicating a
possible relation between CSB and the BER pathway (Tuo et
al., 2002a).
The ubiquitin-binding domain (UBD) is located in the
C-terminal region of the CSB protein (amino acid residues
1400–1428). UBD-CSB–deficient cells have a phenotype
similar to that of cells that do not express the CSB protein at
all. Although the TC-NER complex is fully assembled
around the lesion and RNA pol II in these cells, the repair
does not proceed because of the inability of CSB to leave the
lesion site (Anindya et al., 2010). The replacement of the
CSB UBD by another UBD, such as UBA2 of Rad23, an oth-
erwise unrelated Saccharomyces cerevisiae DNA repair
gene, also enables CSB dissociation from the lesion region
and progression of the repair process, thereby demonstrating
the need for CSB ubiquitination for the correct functioning of
the protein in this TC-NER (Anindya et al., 2010). Cells lack-
ing UBD in the CSB protein are sensitive to oxidatively in-
duced DNA damage (Ranes et al., 2016), suggesting that this
domain is important for the repair of this kind of lesion. The
conserved amino acid lysine at position 911 was recently
found to be a ubiquitination site that is also required for this
function, but is dispensable for TC-NER (Ranes et al., 2016).
By constructing several CSB mutants with different de-
letions in the C-terminal region, Sin et al. (2016) found that
the integrity of the amino acid sequence in this region is im-
portant for this sumoylation of this protein and association
with chromatin. Aside from this region, a functional UBD
domain is necessary for RNA Pol II interaction and CSA re-
cruitment to the nucleus (Sin et al., 2016). In addition,
Groisman (2006) demonstrated that the degradation of CSB
depends on the action of an E3-ubiquitin ligase complex that
contains CSA.
CSA is a 44 kDa protein 396 amino acid residues long
and is encoded by the ERCC8 gene located in chromosomal
region 5q12.1 (Henning et al., 1995). It belongs to the WD-
repeat family because it contains 7 WD40 domains that are
repeated in its structure. These domains consist of approxi-
mately 40 amino acid residues that start with a conserved
glycine and histidine sequence and terminate in tryptophan
and aspartic acid (WD), a seven-bladed propeller structure
with its N terminus attached to DDB1 via a helix-loop-helix
motif (Fischer et al., 2011). Proteins with the WD40 domain
characteristically interact with other proteins and are typi-
cally known for their ability to form protein complexes (Xu
and Min, 2011). Although they do not have a catalytic activ-
ity, they are involved in a variety of cellular functions, such
as the regulation of transcription and chromatin conforma-
tion, apoptosis, signal transduction, and cell cycle control,
among others (Xu and Min, 2011). CSA protein structure and
homozygous/heterozygous pathological alterations are illus-
trated in Figure 3A and B. Table S2 shows all the ERCC8
mutations reported in the literature.
It is known that CSA is part of the E3 ubiquitin ligase
complex, along with DDB1, RBX1, and CUL4A (Groisman
et al., 2003; Fischer et al., 2011), responsible for the ubiqui-
tination and degradation of TC-NER proteins when the repair
is finalized (Groisman et al., 2006). In addition, CSA inter-
acts and complexes with several proteins involved in tran-
scription, ribosomal biogenesis, and TC-NER (reviewed by
Aamann et al., 2014; Koch et al., 2014). Nonetheless, the
mechanisms via which these interactions occur, and which
CSA regions are involved, are not yet completely under-
stood.
The three-dimensional structure and conserved amino
acid residues in specific regions of the protein are of great im-
portance for the regulatory activity and the interactions. Mu-
tations in these regions that lead to the alteration of one of
these factors may inevitably impair these functions (Muftuo-
glu et al., 2002; Christiansen et al., 2003).
To identify a possible relation between the mutations
and the phenotype of patients with CS, we mapped all the
mutations in the ERCC8 and ERCC6 genes and their impact
on proteins CSA and CSB, respectively, that is already re-
ported in the literature. In total, we found 102 mutations in
ERCC6 (50 homozygous and 52 heterozygous) and 37 muta-
tions in ERCC8 (23 homozygous and 14 heterozygous).
These numbers indicate that 70% of all the cases of the dis-
ease are caused by CSB mutations and 30% by CSA muta-
tions. Analyzing only homozygous mutations, we observed
the lack of an obvious correlation between the type of muta-
tion or the affected region with the severity of CS (Tables S1
and S2).
Nevertheless, as discussed by Laugel (2013), the large
prevalence of type I CS clinical classification (moderate phe-
notype) is noted in CSA patients, with most of the mutations
located in the WD domains. Regarding CSB, mutations are
predominant among the domains (such as domains III and IV,
for example) and are mostly nonsense mutations and frame-
shifts, with lower prevalence of missense mutations and dele-
tions. Unlike CSA cases, type II CS clinical manifestation is
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predominant among CSB patients (Laugel, 2013; Calmels et
al., 2018).
The mutations that give rise to truncated CS proteins
and the phenotype of the patients are also non-correlating
variables. Proteins with mutations in the amino acid end se-
quences, such as R1087X, all have the integral ATPase do-
mains but still lead to the manifestation of type II CS (more
severe phenotype). On the other hand, the most striking ex-
ample is the total absence of functional CSB resulting from
the R77X mutation, as reported by Horibata et al. (2004), not
leading to CS manifestation but instead causing UV-sensitive
syndrome (UVSS) (Spivak, 2005). Another interesting ob-
servation is that the same mutation may cause different forms
of CS in different patients. Other examples of one specific
mutation resulting in different phenotypes exist in the litera-
ture. For example, Colella et al. (2000) described two sib-
lings with the R735X mutation in CSB that do not cause CS
but instead induce De Sanctis–Cacchione syndrome (a vari-
ant form of XP), whereas Mallery et al. (1998) described an
association of the same mutation with type I of CS. In addi-
tion, Jaakkola et al. (2010) discovered the R1288X mutation
(in CSB), which causes a severe neurological disorder known
as cerebro-ocular-facial-skeletal syndrome (COFS) in sev-
eral members of the same family, while the same mutation
was also associated with type II CS manifestation (Laugel et
al., 2009). This unexpected difference in phenotypes sug-
gests that the genetic background may be a key factor that
also needs to be taken into account in studies on the develop-
ment, diversification of forms, and manifestations of the dis-
ease.
CS as a transcription syndrome
A deficiency in TC-NER and the consequent inability
to recover RNA synthesis upon DNA damage in actively
transcribed strands of genes could contribute to the neurolog-
ical CS phenotype. Nonetheless, patients with UVSS (which
can be caused by mutations in genes CSA, CSB, or UVSSA)
lack TC-NER and are sun sensitive but do not manifest any of
the neurological symptoms of CS (Itoh et al., 1996; Horibata
et al., 2004; Spivac, 2005; Nardo et al., 2009; Zhang et al.,
2012; Brooks, 2013).
In 1997, both the Hoeijmakers and Sancar groups dis-
covered that CSB associates with RNA pol II, suggesting that
CSB is implicated in transcription (Selby and Sancar,
1997a,b; van Gool et al., 1997). In fact, CSB was shown to
increase the rate of transcription elongation up to threefold in
an in vitro assay that reconstituted the transcription system
(Selby and Sancar, 1997b). Similar observations were made
by Balajee et al. (1997). These results prompted the authors
to suggest that CS may be mainly a transcription, rather than
a DNA repair related syndrome.
Five years later, Bradsher et al. (2002) stated that CSB
was found in the nucleolus in a complex containing RNA pol
I, which regulates ribosomal RNA (rRNA) transcription. The
authors noticed that a CSB mutant cell line showed 8- to
10-fold lower rates of rRNA synthesis than did wild-type
cells, confirming a critical role of CSB not only in mRNA
synthesis (by RNA pol II) but also in rRNA synthesis (by
RNA pol I). Of note, the CSA protein turned out to be associ-
ated with RNA pol I in the nucleolus, and a knockdown of
CSA reduced rRNA synthesis (Koch et al., 2014). This mal-
function in RNA pol I transcription has also been linked to
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Figure 3 - Representation of CSA protein and its seven WD-repeat domains. (A) Homozygous mutations are indicated: frameshifts and nonsense muta-
tions are indicated above the protein, while deletions and missense mutations are indicated below the protein. (B) Represents heterozygous mutations.
endoplasmic-reticulum stress, leading to an unfolded protein
response and the loss of proteostasis, which may be linked to
the CS phenotype (Alupei et al., 2018).
In agreement with the idea that CS is a transcription
syndrome, Newman et al. (2006) found that CSB-null fibro-
blasts feature a gene dysregulation pattern similar to that in-
duced by HDAC inhibitors. Wang et al. (2014) reported
dysregulation of several genes (linked to neurons) in CSB-
mutant and CSA-mutant fibroblasts and in post-mortem brain
tissue of patients. The authors also noticed that in vitro
transdifferentiation of fibroblasts into neurons and neuroblast
differentiation are impaired in CSB-deficient cells. These re-
sults strongly indicate that CSB is critical for neuronal differ-
entiation and maintenance, and that gene expression defects
might underlie the neurodegenerative and the neurodevelop-
mental defects observed in patients.
By taking advantage of cell reprogramming, Andrade
et al. (2012) for the first time reprogrammed CSB-mutated
primary fibroblasts into induced-pluripotent stem cells.
Aside from making it possible to obtain a cell type that can be
used to model CS development in vitro, the authors noticed
dysregulation of hundreds of targets (including p53 and
TXNIP) in these cells (Andrade et al., 2012). More recently,
by combining cell reprogramming with neuron differentia-
tion protocols, Vessoni et al. (2016) were, for the first time,
able to obtain live neurons from patients’ skin fibroblasts. By
RNA sequencing, the authors were able to find that patholog-
ical mutations in the ERCC6 gene changed the expression of
almost 5000 transcripts in neurons of CSB-deficient patients
compared to unaffected controls. Pathways related to axono-
genesis, the action potential of neurons, neurotransmission,
as well as transcripts related to the growth hormone–IGF-1
pathway were found to be dysregulated in the CSB-deficient
neurons. Collectively, these results confirm that CSB defi-
ciency heavily impacts the transcriptional process of the cell
types relevant for the disease, even in the absence of exoge-
nous DNA-damaging agents. Such extensive transcriptional
dysregulation may underlie the complex and heterogeneous
CS phenotype.
Nonetheless, as mentioned before, some mutations in
genes XPB, XPD, XPF, XPG, or ERCC1, which participate in
NER (Menck and Munford, 2014), may result in a combined
phenotype of CS and XP (Lehmann 1982, 2014; Weeda et al.,
1990; Moriel-Carretero et al., 2015). How can we explain the
CS phenotype in all these cases? A likely answer to this ques-
tion may depend on a multiprotein complex, TFIIH, which is
indispensable for NER and for transcription. TFIIH consists
of two functional subcomplexes (Core and CAK) that partici-
pate in initiation, promoter escape, and early elongation
(Compe and Egly, 2012). The core subcomplex consists of
seven proteins, including 3’ to 5’ ATP-dependent helicase
XPB, and XPD, a 5’ to 3’ ATP-dependent helicase that binds
to the core and CAK complexes together and facilitates opti-
mal transcription (Tirode et al., 1999; Egly and Coin, 2011).
In this sense, two mutations in the XPB gene (associated with
the XP/CS phenotype) reduce transcriptional activity in a re-
constituted transcription assay in vitro (Coin et al., 1999).
Moreover, XPD or XPB mutations associated with CS were
found to disrupt the interactions among CSB, TFIIH, and
RNA pol I (Bradsher et al., 2002). The XPG nuclease was
also found to associate with and stabilize TFIIH, and muta-
tions in the XPG gene related to an XP-G/CS phenotype abro-
gate the XPG–TFIIH interaction (Ito et al., 2007; Lehmann et
al., 2014; Narita et al., 2015). The recently described XP/CS
patients with mutations in XPF or ERCC1 (Kashiyama et al.,
2013) pose a challenge to the “CS as a transcription syn-
drome” point of view, because XPF/ERCC1 is implicated in
NER and not in basal transcription. Although XPF is re-
cruited to the promoter of inducible genes (to facilitate chro-
matin modification for transcription) in the absence of exoge-
nous DNA damage, other NER factors are recruited as well,
including XPC, in which mutations do not result in neurolog-
ical abnormalities (Le May et al., 2010). XPF mutations that
cause the XP/CS phenotype were recently found to cause per-
sistent recruitment of NER proteins to DNA damage sites,
which may induce the stalling of RNA and DNA poly-
merases, thereby interfering with the transcription and repli-
cation processes (Sabatella et al., 2018). Nevertheless, en-
dogenous levels of DNA lesions that are substrates for NER
have been reported to accumulate in mammalian cells and tis-
sues to the levels that would not be consistent with the notion
of defective TC-NER as a cause of the neurological symp-
toms of CS (Brooks, 2013). Therefore, more studies are
needed to clarify the mechanism behind XPF/ERCC1 muta-
tions and the development of the CS phenotype in these pa-
tients (Kashiyama et al., 2013).
CS and redox processes
The manifestation of CS occurs only when some NER
proteins are mutated, while the complete deactivation of this
pathway, via mutations in XPA, leads to the development of
XP. Consequently, the roles of proteins CSA and CSB in ad-
dition to those known classic functions come into question. In
addition, the main symptoms of patients with CS, e.g., neuro-
logical aberrations, cannot be explained only by the ineffi-
cient repair of UV damage because neurons are not exposed
to this type of radiation. Due to the systemic presence of reac-
tive species and their ability to chemically and structurally
modify biomolecules, especially DNA, these compounds
have been investigated as possible contributing factors of CS.
Experiments with keratinocytes derived from patients
with CS suggest that these cells contain high concentrations
of reactive oxygen species (ROS) with redox balance alter-
ations under baseline conditions, characteristics that are re-
lated to the senescence phenotype of these cells (Cordisco et
al., 2018). The induction of redox processes by the exposure
of mice and CSB-/- mouse embryonic fibroblasts to ionizing
radiation or paraquat revealed high sensitivity to the toxic ef-
fects of these agents, while such high sensitivity is not ob-
served in CSA-mutant mice (de Waard et al., 2003, 2004).
The sensitivity to the redox processes was also observed in
CSA-/- keratinocytes and fibroblasts treated with potassium
bromide (D’Errico et al., 2007) and in CSB-/- cells exposed to
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MMS (methyl methansulfonate) and 5-hydroxymethyl-
2’deoxyuridine (Wong et al., 2007).
Moreover, lipid peroxidation products such as HNE
(4-hydroxynonenal) at high cellular concentrations perform
direct modifications on the CSB protein, compromising its
ATPase activity required for the DNA repair by TC-NER
(Maddukuri et al., 2009). On the other hand, Boetefuer et al.
(2018) demonstrated that this activity is not needed for
CSB–chromatin association when CS1AN-sv cells are ex-
posed to menadione. In that condition, these associations are
loci-specific and are stimulated by the PARP1 protein, there-
by indicating possible participation of CSB in the transcrip-
tional regulation in response to oxidative stress (Boetefuer et
al., 2018a). These findings are in agreement with previous re-
sults that point to the involvement of a CSB function in this
process, thereby showing that CSB localization and interac-
tion with transcriptional repressor CTCF in promoter regions
are greater in cells under oxidative stress (Lake et al., 2016;
Boetefuer et al., 2018b).
Although DNA oxidation products are typically re-
paired by the BER pathway, it has been demonstrated that
BER and NER proteins not only show crosstalk, but also that
some oxidatively generated lesions are substrates for the
NER pathway (D’Errico et al., 2007; Berra et al., 2013). For
example, 8-oxoGua, thymine glycol, malondialdehyde, and
etheno adducts induce distorting modifications in the double
helix and have the potential to block transcription (reviewed
by Tornaletti, 2005; Chaim et al., 2017), with cyclopurines
being DNA oxidation products that are repaired only by NER
(Brooks et al., 2000). Numerous experiments have confirmed
the importance of the CSA and CSB proteins for the repair of
oxidized bases, by demonstrating that in the absence of CSA
or CSB there is accumulation of 8-oxoGua in DNA (Dianov
et al., 1999; Tuo et al., 2001; D’Errico et al., 2007; Aamann
et al., 2014a; Cordisco et al., 2018). 8-OH-Ade, 5-hydro-
xycytosine, and cyclopurines are also lesions that are ineffi-
ciently repaired in cells harboring mutations in CS genes
(Tuo et al., 2002b, 2003; D’Errico et al., 2013). Because of
the inefficient repair in the cells of important tissues such as
the brain, the accumulation of these lesions in DNA may be
one of the factors that cause and aggravate the neurological
symptoms of the disease, as seen in patients with neuro-
degenerative diseases, such as Alzheimer’s, Parkinson’s,
Huntington’s disease, and amyotrophic lateral sclerosis
(Ayala-Peña, 2013; Coppedè et al., 2016; Abolhassani et al.,
2017).
The mutational impact of oxidatively induced DNA
damage in CS was investigated by Lodato et al. (2018). By
means of single-cell whole-genome sequencing followed by
genome-wide somatic single-nucleotide variant identifica-
tion, they detected an increased number of mutations in the
neurons of patients with CS as compared to the control. In ad-
dition, C > A variants, a signature for mutations induced by
oxidatively induced DNA damage, are found in a higher fre-
quency among patients with CS (Lodato et al., 2018).
It is noteworthy that in response to irradiation or hydro-
gen peroxide, CSA is translocated to the nuclear matrix by a
CSB-dependent mechanism (Kamiuchi et al., 2002), but as
discussed above, these two proteins perform different func-
tions in chromatin remodeling and in recruitment of the fac-
tors associated with the repair and blocking of RNA pol II in
vivo (Fousteri et al., 2006). This cooperation between CSA
and CSB was not observed in response to treatment with
alkylating agents and is independent of XPA and XPC, thus
suggesting that TC-NER plays a key part in this cellular re-
sponse mechanism (Kamiuchi et al., 2002).
Brain biopsies of CS and XPA patients yielded distinct
results in response to the accumulation of oxidized bases in
DNA and SOD expression, with only XPA-mutant patients
showing upregulation of 8-oxoGua in the nucleus and alter-
ation in SOD expression (Hayashi et al., 2005).
In addition to the participation of these proteins in the
repair of oxidation-induced lesions through the NER path-
way, there is also a contribution to the removal of DNA dam-
age via direct and indirect activity in the BER pathway
(Khobta and Epe, 2013). This contribution is mediated by the
direct modulation through interactions of CSB with BER
protein glycosylases, APE1, NEIL1 and NEIL2, and associa-
tion with the OGG1 complex, which stimulates the incision
activity of these proteins and drives the repair (Wong et al.,
2007; Muftuoglu et al., 2009; Aamann et al., 2014b).
Csbm/m/Ogg1-/- mice show high concentrations of 8-oxoGua
in comparison with Ogg1-/- animals, thereby confirming the
importance of the cooperation between these two proteins in
the removal of these lesions (Osterod et al., 2002; Trapp et
al., 2007). Pastoriza-Gallego et al. (2007) also demonstrated
that the 8-oxoGua lesions exert different effects on gene ex-
pression depending upon the promoter and sequence context,
and that both proteins, Csb and Ogg1, are required for full re-
pair.
Recent evidence also indicates that CSB recruits the
XRCC1 protein to single-strand break regions after oxida-
tively induced DNA damage for subsequent processing by
BER (Menoni et al., 2018). In the indirect modulation of the
BER pathway, CSB acts as an important factor in the expres-
sion of hOGG1, inducing its transcription. It has also been
observed that in CSB-deficient cells, the amounts of OGG1
mRNA and protein are low (Dianov et al., 1999; Tuo et al.,
2002a; Aamann et al., 2014b).
Some studies point to a possible implication of CSB in
the repair of oxidized bases in genomic and mitochondrial
DNA, to CSB migration to mitochondria, and modulation of
p53 activity in response to a redox process (Stevnsner et al.,
2008; Frontini and Proietti-De-Santis, 2009; Aamann et al.,
2010).
The repair of oxidized bases also has a fundamental
role for the mitochondria. These organelles produce ATP
through the electron transport chain, a process that not only
provides cells with energy, but also produces ROS as a
by-product of respiration (reviewed by Kowaltowski et al.,
2009). For this reason, mitochondria are also considered the
primary source of ROS in cells, having a much more oxidiz-
ing environment within the mitochondrial matrix as com-
pared with the cellular cytosol (Hu et al., 2008).
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Because of proximity to the initial site of formation and
constant exposure to ROS, mitochondrial DNA (mtDNA) is
the main target of these molecules, and just as nuclear DNA,
it is susceptible to oxidation in the DNA bases and undergoes
other modifications in its structure (reviewed by Muftuoglu
et al., 2014). Besides, the accumulation of lesions in mtDNA
causes instability and compromises its functioning, which
can lead to mutations and affect genes that are important for
mitochondrial metabolism. In addition, various aging-related
diseases, such as cardiovascular diseases, Parkinson’s dis-
ease, Alzheimer’s disease, and cancer are associated with
significant amounts of lesions in mitochondria, thus being
considered one of the causes of the pathologies related to mi-
tochondrial dysfunction (Mecocci et al., 1994; Ide et al.,
2001; Stichel et al., 2007; Wallace, 2012).
Mitochondria have some specific repair pathways,
such as BER and mismatch repair (MMR). As in the repair of
nuclear DNA, the CSA and CSB proteins are present and par-
ticipate in this process, even though there is no mitochondrial
NER (Kamenisch et al., 2010). It has been demonstrated that
CSA and CSB, after induction of redox processes by the ex-
posure to H2O2, UV, or menadione, are directed toward mito-
chondria and interact with OGG1 (Aamann et al., 2010;
Kamenisch et al., 2010; reviewed by Prates Mori and de
Souza-Pinto, 2018). In mitochondria, CSB may act as a mod-
ulator of the BER pathway, in association with the inner mi-
tochondrial membrane for mtDNA lesion removal (Stuart et
al., 2005; Aamann et al., 2010). In fact, CSBm/m mice accu-
mulate 2.5-fold more 8-oxoGua in mtDNA than wild-type
animals (Osenbroch et al., 2009). The mutation in CSBm/m
mice is the same as that in the ERCC6 gene of the CS1AN pa-
tient, K337  stop, which generates a truncated nonfunc-
tional protein (Troelstra et al., 1992; van der Horst et al.,
1997).
In addition to the influence on DNA repair, CSB is in-
volved in gene expression by engaging in the elongation by
RNA polymerase II (Selby and Sancar, 1997a). In in vitro
transcription, through interactions with proteins of the mito-
chondrial nucleoid complex, CSB promotes POLRMT trans-
criptional elongation and allows it to access mtDNA by
TFAM removal from the region to be transcribed (Berquist et
al., 2012).
Regarding CS mitochondrial metabolism, Scheibye-
Knudsen et al. (2012) reported a significant increase of this
metabolism in both CSBm/m mice and CSB-deficient cells,
and this phenomenon is also manifested in CSA- or CSB- de-
ficient fibroblasts and CSA-/-/XPA-/- mice (Pascucci et al.,
2012; Brace et al., 2016). This increase in energy metabolism
is accompanied by a large production of ROS through elec-
tron leakage (Pascucci et al., 2012; Cleaver et al., 2014), and
is the main source of DNA damage induction (Scheibye-
Knudsen et al., 2012) and of changes in the membrane poten-
tial, excessive fragmentation, and mitochondrial fission (Pas-
cucci et al., 2012, 2016).
Under normal cell conditions, organelles and defective
proteins are eliminated by autophagy. On the other hand, dys-
functional or damaged mitochondria are subjected to a spe-
cial form of autophagy, called mitophagy (Fivenson et al.,
2017). This mechanism contributes to cell homeostasis, and
its malfunction is present in several aging-related diseases
(reviewed by Redmann et al., 2014). Human and murine
CSB-mutant fibroblasts feature a dysfunction in this pathway
owing to defects in the recruitment of P62, an essential player
in mitophagy (Scheibye-Knudsen et al., 2012).
Thus, dysfunctional mitochondria, with large amounts
of mtDNA lesions, can produce more ROS via their metabo-
lism. Consequently, ROS accumulate in the cells, promoting
apoptosis (Pinto and Moraes, 2015; van Houten et al., 2016),
which might be associated with reduced amounts of subcuta-
neous fat in CSA-/- and CSBm/m mice (Kamenisch et al.,
2010). Treatment with pharmacological activators of auto-
phagy, such as rapamycin (Scheibye-Knudsen et al., 2012)
and an HDAC inhibitor (Majora et al., 2018), attenuates the
accumulation of damaged mitochondria in CSB-deficient
cells and the loss of subcutaneous fat in CSBm/m mice.
Models for CS study
To better understand the mechanisms of CS progres-
sion, several animal models have been developed for re-
search on the disease, e.g., mice, Caenorhabditis elegans,
and zebrafish. In general, such models carry knockout muta-
tions or mutations identical to those found in humans, en-
abling a more accurate analysis in different cells and tissues
of an organism.
The first models generated to study CS were created on
the basis of mice with the C57BL/6 background - CSBm/m
mice (van der Horst et al., 1997), and CSA-/- mice (van der
Horst et al., 2002). In CSA-/- cells, the interruption of the gene
sequence in exon 2 of the Ercc8 gene results in protein ab-
sence (van der Horst et al., 2002). When exposed to UV, the
fibroblasts of these animals manifest higher UV sensitivity,
and they have an inability to resume RNA synthesis and de-
fective TC-NER, these being the classic characteristic of CS
(Lehmann, 1982; van der Horst et al., 1997, 2002).
The CSBm/m and CSA-/- models have similar pheno-
typic characteristics, although neither has the severe neuro-
degenerative phenotype and lifespan reduction seen in
patients with CS. Despite differences between them, these
mouse models have a few characteristics that resemble their
human counterpart, such as the tendency toward reduced
body weight via a decrease in the amounts of subcutaneous
and visceral fat (Gorgels et al., 2007; Scheibye-Knudsen et
al., 2012), mild neurological dysfunction with changes in
myelin (Jaarsma et al., 2011), activation of glial cells in
white-matter regions (Jaarsma et al., 2011), progressive deaf-
ness (Nagtegaal et al., 2015), photophobia and sensitivity to
UV exposure (van der Horst et al., 1997, 2002). In contrast to
what is manifested in humans, the mouse models are prone to
skin and eye cancers when exposed to UV, a feature that can
be explained by the inefficiency of murine GG-NER in deal-
ing with UV-induced cyclobutane pyrimidine dimer-like le-
sions, which are preferentially repaired by TC-NER (van der
Horst et al., 1997, 2002; de Boer and Hoeijmakers, 1999).
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CSBm/m cells (from several tissues, mainly the brain
and kidneys) also contain high levels of formamidopyri-
midines and 8-oxoGua in DNA when compared to wild-type
mice (Muftuoglu et al., 2009). In addition to nuclear DNA
damage, mtDNA damage and mutational load in the mtDNA
of CSA-/- and CSBm/m mice increased during aging and is re-
lated to subcutaneous fat loss, one of the main characteristics
of CS, probably mediated by the apoptosis caused by mito-
chondrial dysfunction (Kamenisch et al., 2010) and by cell
senescence, a feature commonly present in progeroid models
(Carrero et al., 2016).
The combined deletion of other NER proteins such as
XPA in these CS mice leads to a more severe phenotype.
These animals manifest severe neurological symptoms,
ataxia, compromised growth, low weight, a lack of motor co-
ordination, kyphosis, and abnormal behavior and develop-
ment with premature death within 20 days (Murai et al.,
2001; van der Pluijm et al., 2007). Inactivation of GG-NER
by an XPC knockout in CSBm/m mice leads to a similar phe-
notype, with dysmyelination, slow development, and low
body weight: characteristics that resemble those of patients
with CS (Laposa et al., 2007; van der Pluijm et al., 2007; Re-
vet et al., 2012). CSA-/-/XPA-/- mice also show evidence of
neurological problems, life expectancy reduced to ~1 month,
an increase in cellular oxidative phosphorylation, and lipo-
dystrophy (Brace et al., 2013, 2016).
The mechanism that underlies this aggravation of the
CS phenotype by the double inactivation of CS and XP genes
in mice has yet to be uncovered. Since CS and XP proteins act
in the same DNA repair pathway, it is assumed that this se-
vere CS phenotype in mice is due to the disruption of both
NER-related and other functions of the CS proteins, such as
transcription regulation (Brooks, 2013) and/or interactions
with other DNA repair pathways (Murai et al., 2001). Inacti-
vation of NER by an XPC or XPA gene knockout can result in
the accumulation of transcription-blocking DNA lesions, and
the loss of either CS protein may further interfere with tran-
scription and further increase the DNA damage load, which
can in turn have detrimental effects, such as cell death or
early cell senescence, both of which have been observed in
progeroid mice (Weeda et al., 1997; van der Pluijm et al.,
2007; Brooks, 2013).
Combined inactivation of TC-NER and NER in neu-
rons has also been reported to generate an age-related pro-
gressive neurodegenerative phenotype. CSBm/m mice featur-
ing a neuron-specific conditional XPA knockout have a
shorter lifespan, behavioral abnormalities, and brain atrophy.
These characteristics are possibly related to a synergistic ef-
fect of the TC-NER and NER pathways or to other functions
of the inactivated proteins, such as chromatin remodeling or
other functions in transcription (Newman et al., 2006; Jaars-
ma et al., 2011; Wang et al., 2018). Cell type–specific condi-
tional knockouts may also help to better understand the parti-
cipation of other processes in the progression of the disease,
along with their molecular mechanisms, e.g., the role of
oligodendrocytes (Howng et al., 2010) or other glial cells
(Raj et al., 2014) in CS dysmyelination and in the neuro-
degenerative phenotype.
Mutations in XPG or ERCC1 can yield mice with the
characteristics similar to those of CS and other diseases on
the CS spectrum, such as XP/CS and COFS (Jaarsma et al.,
2013). These NER nuclease–deficient models have several
neurodegenerative features, altered metabolism, and a re-
duced lifespan (Weeda et al., 1997; Barnhoorn et al., 2014).
Notably, despite the lipodystrophy observed in all these ani-
mal models, dietary restriction and methionine restriction
(which are metabolic interventions known to increase the
lifespan of several species) reversed some of the neuro-
degeneration indicators of the CSA-/-/XPA-/- and ERCC1/-
models, with dietary restriction nearly doubling the lifespan
of ERCC1/- mice. This finding indicates that metabolic in-
terventions are a possible therapy for NER-related progeroid
diseases (Brace et al., 2016; Vermeij et al., 2016).
The current murine models for CS research do not fully
reproduce the phenotype seen in humans because these ani-
mals manifest milder symptoms of the disease when only a
single TC-NER protein is mutated. One of the possible expla-
nations is the adaptation of NER to deal with DNA damage
that would be repaired initially by CSA and CSB. This ex-
plains the severe symptoms when both TC-NER and NER are
inactivated (van der Pluijm et al., 2007). In this case, it is im-
portant to consider the evolutionary distance that separates
mice from humans. This distance entails differences in gene
expression and metabolic and physiological profiles, among
others (Seok et al., 2013; Lin et al., 2014). Such differences
contribute to the following phenomenon: the phenotype re-
sulting from the same mutation and the activity of the repair
pathway are not identical between the two species. Table 1
summarizes the mouse models carrying mutations in CS
genes and other single-NER-mutation models that recapitu-
late CS-like phenotypes.
Different animal models of lower complexity have also
been developed to study the role of CSA and CSB proteins,
and are an interesting alternative for the research into protein
functions. Among these models are Caenorhabditis elegans
and zebrafish.
C. elegans has advantages, such as the ease of labora-
tory maintenance, of genetic manipulation, of tissue differen-
tiation, rapid reproduction with several offspring, a generally
fixed and genetically determined number of cells, and a short
life cycle, allowing for the study of its development within
short periods. It has been demonstrated that the NER pathway
is well conserved in C. elegans, resembling the repair mecha-
nisms of mammals (Meyer et al., 2007; reviewed by Lans and
Vermeulen, 2011), and because they do not repair DNA by
photoreactivation (Hartman et al., 1989). Rather, the lesions
caused by UV are repaired exclusively by NER. CSA and
CSB analogs, csa-1 (Babu et al., 2014) and csb-1 (CeCSB)
(Lee et al., 2002), respectively, were found to be a part of this
pathway. Animals mutated in csa-1 are hypersensitive to
UV-B light exposure (Babu et al., 2014), and csb-1–deficient
animal germ cells show apoptosis induction and morphologi-
cal abnormalities after exposure to this agent (Lee et al.,
10 Vessoni et al.















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2002). Moreover, a knockout of either csa-1 or csb-1 in C.
elegans resulted in increased oxygen consumption and in
changes in the transcription of genes related to mitochondrial
ATP production, ubiquitin pathways, and transcriptional reg-
ulation (Scheibye-Knudsen et al., 2016).
In general, C. elegans is a good model for the investiga-
tion of the DNA damage response to UV via the NER path-
way, because this species makes it possible to reproduce and
examine the effects of irradiation or other DNA-damaging
agents on an entire organism and throughout its developmen-
tal stages within a short period of time.
The zebrafish is a vertebrate model that is widely used
in research on the effects of exposure to genotoxic agents,
carcinogenesis processes, and mainly embryonic develop-
ment (Spitsbergen and Kent, 2003; Titus et al., 2009). This
animal has orthologous DNA repair genes in the pathways
present in higher eukaryotes, e.g., BER, NER, MMR,
Non-homologous end joining and Homologous recombina-
tion (Pei and Strauss, 2013). In NER, 44 genes are responsi-
ble for the functioning mechanisms of damage removal.
Despite this observation, there are still few zebrafish studies
where these characteristics are exploited from the perspective
of DNA repair alone.
Zebrafish with the CSB depleted by morpholino
oligonucleotides at the larval stage show an increased fre-
quency of morphological abnormalities, which may recapitu-
late some of the congenital and developmental
manifestations seen in patients with CS. Ionizing radiation
can further increase morphological aberrations in
CSB-depleted zebrafish, thereby pointing to an important
role of CSB in the defense against oxidative DNA damage
(Wei et al., 2015).
Due to the complexity of CS and the unique character-
istics of patients with CS, which cannot be fully recapitulated
in any animal model, a combination of human cell models
with various animal models offers complimentary ap-
proaches to elucidate the various characteristics of this syn-
drome. In this sense, the use of somatic cell reprogramming
coupled with genome editing allows investigators to obtain
relevant and functional cell types (such as neurons) carrying
patient-specific mutations. Moreover, this method offers an
opportunity to investigate how the genetic background of dif-
ferent patients interacts with the one given pathological mu-
tation. Such an approach may clarify why certain patients that
share the same mutation in a CS gene have different pheno-
types (Colella et al., 2000).
Conclusion
Almost 60 years of accumulated research in the NER
field, especially regarding progeroid CS, provides extensive
knowledge about the structure of proteins CSA and CSB and
their participation in TC-NER and other mechanisms, such as
transcription, repair, and mitochondrial functioning. For the
advances made so far, human cellular models and animal
models have been invaluable. They have revealed that the CS
phenotype is likely a combination of altered gene transcrip-
tion, metabolic adjustment, redox imbalance, and DNA re-
pair defects, although the relative importance of each of these
mechanisms for the disease is still largely unknown. More-
over, the full spectrum of the syndrome is not completely
mirrored in animals, and this situation undoubtedly hinders
further research. This difficulty is also associated with the
impossibility of correlation between the mutations in
ERCC6/ERCC8 genes and the phenotype of the patients, sug-
gesting that the genetic background can heavily influence the
manifestation of the symptoms.
Recently, the ability to generate pluripotent stem cells
from patients with CS enabled for the first time the recapitu-
lation of the full genetic signature of a patient in a cell type
relevant for the disease, e.g., neurons. This observation ex-
pands and complements the previous CS models because it
enables the investigation of metabolism, of the DNA damage
response, and of gene expression in a patient’s cells. These
data were previously impossible or very difficult to obtain.
Still, one needs to keep in mind that CS is a systemic disease,
and for this reason, investigating how dysfunction in one tis-
sue/organ impacts others is critical. All these difficulties re-
veal how complex and diverse CS is and imply that a
multimodel approach will therefore help to better recapitulate
certain characteristics of CS. Moreover, although not entirely
equivalent to normal aging, CS has clinical and cellular simi-
larities to some aging-related diseases. Thus, improvements
of (and new approaches to) CS models may have a broad im-
pact on the study of these diseases as well.
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